IBS

Business briefs: Boehringer Ingelheim, Sanofi, GSK, Teva

BI cancer drug lands breakthrough therapy designation; Sanofi tallies two European MS drug approvals; GSK terminates testing for a Crohn's drug; and Teva joins cancer collaboration

Forest's one-a-day IBS drug Linzess to take on Amitiza

Forest's one-a-day IBS drug Linzess to take on Amitiza

By

Forest and Ironwood IBS drug Linzess (linaclotide), which won FDA approval last week for treatment of chronic constipation and irritable bowel syndrome with constipation, is expected by some analysts to become a blockbuster.

Email Newsletters